A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects.

Abstract

This first-in-human, phase I study evaluated the safety, tolerability, pharmacokinetic and pharmacodynamic profile of ASKP1240 in healthy subjects. Twelve sequential groups (each 6 active and 3 placebo) were randomly assigned to placebo or single ascending doses of intravenous ASKP1240 (0.00003-10 mg/kg). ASKP1240 exhibited nonlinear pharmacokinetics, with… (More)
DOI: 10.1111/ajt.12082

Topics

Cite this paper

@article{Goldwater2013AP1, title={A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects.}, author={Ruth Goldwater and James J. Keirns and Paul C. Blahunka and R G First and Taiji Sawamoto and W. Zhang and David Kowalski and Atsushi Kaibara and J. Holman}, journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons}, year={2013}, volume={13 4}, pages={1040-1046} }